LifeSensors社 Designing K-RAS Degraders to Overcome Drug Resistance
|
この製品に関するご意見・ご照会・お問合せはこちら
|
Designing KRAS Degraders in Cellular-Based Assays
|
|
|
|
Targeting Oncogenic KRAS
The K-RAS oncogene is a compelling drug target due to its mutation frequency in several cancers. Protein degradation mechanisms as a therapeutic strategy is undergoing revolutionary advances at LifeSensors.
Cancers become resistant to classic K-RAS inhibitors. Discovering novel degraders by applying PROTAC/molecular glue mediated in vitro or in vivo ubiquitination and degradation, simultaneously, will overcome drug resistance.
|
|
|
|
| K-RAS-based degraders with PROTAC and molecular glue mediated ubiquitination, featuring a suite of tools and assays. |
|
LifeSensors' suite of assays is designed to study PROTAC and molecular glue-mediated ubiquitination and degradation of proteins of interest. Identify suitable ligases and provide mechanistic insights that help chemists rationally design potent PROTACs and molecular glues.
|
|
|
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。
